Nabriva Therapeutics Plc (NBRV)

$NBRV 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

CEO

Theodore Schroeder

Exchange

NASDAQ

Website

www.nabriva.com

$20M

Total Revenue

72

Employees

$23M

Market Capitalization

-0.37

Price/Earning ratio

Similar Companies

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 21578 2286 2.88 20.15 13.26
Organon & Co. OGN 7323 7878 -4.52 4.82 19.26
Arvinas Inc ARVN 3963 23 4.93 -19.95 -794.96
Tilray Inc TLRY 2976 564 0.99 -7.48 -66.49
Usana Health Sciences Inc USNA 2079 1230 4.83 15.14 11.04
ATAI Life Sciences N.V. ATAI 1782 20 3.94 -10.71 -821.63
Cronos Group Inc CRON 1527 57 0.96 -10.58 -258.59
DICE Therapeutics Inc DICE 1211 1 3.72 -30.64 None
NRX Pharmaceuticals Inc NRXP 1170 2321 0.45 5.05 9.91
Intersect ENT Inc XENT 894 104 56.42 -10.10 -85.02
Ventyx Biosciences Inc VTYX 877 -10.72 -10.48 None
Phibro Animal Health Corp. PAHC 825 853 3.49 16.77 5.70
Edgewise Therapeutics Inc EWTX 793 2.79 -21.86 None
Phathom Pharmaceuticals Inc PHAT 673 5.72 -4.13 None
Theseus Pharmaceuticals Inc THRX 567 -12.12 -26.25 None
Cyteir Therapeutics Inc CYT 548 2.80 -15.36 None
Rani Therapeutics Holdings Inc RANI 514 3 9.84 -25.43 -678.00
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Pliant Therapeutics Inc PLRX 475 10 2.16 -5.04 -914.12
Fulcrum Therapeutics Inc FULC 472 18 2.59 -6.30 -409.62
Ikena Oncology Inc IKNA 465 11 2.28 -7.38 -581.21
Provention Bio Inc PRVB 399 1 3.08 -3.27 None
Rain Therapeutics Inc RAIN 350 413 2.42 -9.15 123.20
Chromadex Corp CDXC 299 65 8.71 -10.53 -42.83
Adicet Bio Inc ACET 279 10 1.52 4.84 -570.14
Verrica Pharmaceuticals Inc VRCA 241 12 6.26 -6.30 -320.98
Evolus Inc EOLS 239 86 3.10 -1.40 -162.78
Milestone Pharmaceuticals Inc MIST 231 15 1.32 -7.52 -230.90
Aquestive Therapeutics Inc AQST 194 47 -3.59 -3.11 -132.11
Terns Pharmaceuticals Inc TERN 193 1.13 -5.54 None
Cognition Therapeutics Inc CGTX 185 -2.24 -15.75 None
Anebulo Pharmaceuticals Inc ANEB 149 7.62 -3.81 None
Citius Pharmaceuticals Inc CTXR 134 1.68 -5.85 None
Opiant Pharmaceuticals Inc OPNT 134 44 3.01 107.00 3.58
Kaleido Biosciences Inc KLDO 132 1 4.80 -1.48 None
Xeris Biopharma Holdings Inc XERS 124 35 -100.00 -1.36 -265.78
scPharmaceuticals Inc SCPH 115 119 1.85 -4.10 -27.05
Kala Pharmaceuticals Inc KALA 107 12 1.84 -0.85 None
LifeMD Inc LFMD 107 78 -6.93 -0.96 -95.77
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Eyenovia Inc EYEN 94 6 24.00 -4.74 -332.81
Eton Pharmaceuticals Inc ETON 92 16 5.75 -8.36 -67.52
Natural Alternatives Internati NAII 78 177 0.97 6.99 6.64
Osmotica Pharmaceuticals Plc OSMT 76 166 1.83 -0.75 -60.32
Mannatech Inc MTEX 70 159 2.68 9.09 5.00
Odonate Therapeutics Inc ODT 58 0.83 -0.57 None
India Globalization Capital In IGC 58 0 2.05 -5.00 -981.18
Context Therapeutics Inc CNTX 57 -2.81 -8.19 None
Assertio Holdings Inc ASRT 55 108 0.65 -1.32 -28.04
Shineco Inc SISI 55 3 2.23 -1.07 None
VYNE Therapeutics Inc VYNE 46 17 0.85 -0.83 -507.13
Shineco Inc TYHT 44 3 2.17 -1.55 -159.60
Reviva Pharmaceuticals Holding RVPH 39 1.52 -4.50 None
Acasti Pharma Inc ACST 29 0 0.47 -2.16 -611.47
Bio-Path Holdings Inc BPTH 25 0 1.02 -2.73 18.96
Nabriva Therapeutics Plc NBRV 23 20 0.63 -0.37 -266.57
Baudax Bio Inc BXRX 21 1 -1.35 -0.45 9.10
Cyanotech Corp. CYAN 21 35 1.15 10.12 6.09
Lexaria Bioscience Corp LEXX 20 1 2.76 -5.10 -445.15
Dermata Therapeutics Inc DRMA 20 0.45 -2.46 None
Trevi Therapeutics Inc TRVI 19 2.16 -0.54 None
Hoth Therapeutics Inc HOTH 16 1.45 -1.50 None
Timber Pharmaceuticals Inc TMBR 13 0 11.00 3.07 -527.55
Sonoma Pharmaceuticals Inc. SNOA 9 17 3.02 -1.72 -31.96

Stock Forecast: Nabriva Therapeutics plc (NASDAQ: NBRV) To Slash -381.93% In Near Future

5d ago, source: stocksregister

Nabriva Therapeutics plc (NASDAQ:NBRV) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.85% to the ...

Boiling and ready to burst as Nabriva Therapeutics plc (NBRV) last month performance was -32.27%

2d ago, source: investchronicle

Let’s start up with the current stock price of Nabriva Therapeutics plc (NBRV), which is $0.78 to be very precise. The Stock rose vividly during the last session to $0.8432 after opening rate of $0.83 ...

NBRV Stock Forecast 2021: Nabriva Therapeutics plc Remains Weak With A Downside Of -4.4%

11d ago, source: marketingsentinel

In the last trading session, 1.24 million shares of the Nabriva Therapeutics plc (NASDAQ:NBRV) were traded, and its beta was 1.66. Most recently the company’s share price was $0.91, and it changed ...

Highlights from the Ratings and Financial Report for Nabriva Therapeutics plc (NBRV)

11d ago, source: newsheater

Nabriva Therapeutics plc (NASDAQ:NBRV) went down by -7.60% from its latest closing price compared to the recent 1-year high ...

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

4d ago, source: Associated Press

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today ...

The Future Of Nabriva Therapeutics plc (NASDAQ: NBRV) In 2021

14d ago, source: stocksregister

Nabriva Therapeutics plc (NASDAQ:NBRV) price on Thursday, November 18, fall -3.45% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.98. A look at the ...

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

22d ago, source: Middle East North Africa Financial Network

Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat ...

Nabriva Therapeutics (NBRV) Sees Hammer Chart Pattern: Time to Buy?

12d ago, source: Yahoo Finance

Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Nabriva Therapeutics AG (NBRV) : Free Stock Analysis Report To read this article on Zacks.com click here.

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

4d ago, source: Yahoo Finance

About Nabriva Therapeutics plc Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections ...

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

3d ago, source: Benzinga.com

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of ...

Your Portfolio